A new single-tablet HIV regimen proved non-inferior to multi-pill treatments in a phase-3 clinical trial announced earlier this year [1].
This development is significant because it addresses the "pill burden" faced by long-term survivors. For some patients, existing treatment plans can require up to 11 tablets per day [2], leading to challenges with adherence and quality of life.
The investigational regimen consists of bictegravir 75 mg and lenacapavir 50 mg [3]. Data from the ARTISTRY trial, led at Queen Mary University of London, indicates the combination is well tolerated and as effective as the more complex regimens it aims to replace [1].
Professor Chloe Orkin, a leading HIV researcher, said patients frequently ask why they cannot have a single pill. The shift toward simplification is particularly vital for older patients and those in regions like South Africa, where treatment access and adherence are critical for public health [1].
Orkin said the BIC/LEN regimen was non-inferior to multi-pill regimens and was well tolerated [1]. By condensing multiple medications into one daily dose, the treatment may reduce the risk of missed doses, a primary cause of drug resistance.
Experts said the results are a potential breakthrough for a growing cohort of long-term HIV survivors who have lived with the virus for decades [4]. These patients often face cumulative toxicity from years of various medications, making a streamlined regimen a priority for clinical care.
“"Why can't I have a single pill?"”
The transition from multi-pill to single-tablet regimens represents a shift in HIV care from mere survival to long-term wellness. By reducing the daily medication load from as many as 11 pills to one, healthcare providers can improve patient adherence and reduce the psychological burden of chronic illness, potentially lowering the rate of viral rebound and transmission in high-burden regions.
